Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.

Anne Troldborg Marianne Kragh Thomsen Lars Erik Bartels Jakob Bøgh Andersen Signe Risbøl VilsClara Elbæk MistegaardAnders Dahl Johannsen Marie-Louise From Hermansen Susan Mikkelsen Christian Erikstrup Ellen Margrethe Hauge Christian Ammitzbøll

Published in: The Journal of rheumatology (2022)

Patients with RDs treated with RTX have a severely impaired serological response toward COVID-19 mRNA vaccines. Our data suggest that the current recommendations of a 6-month interval between RTX treatment and vaccination should be reevaluated.

Keyphrases

coronavirus disease
sars cov
immune response
electronic health record
combination therapy
big data
respiratory syndrome coronavirus
artificial intelligence
smoking cessation